Annualized relapse rate (ARR, MS)
Neurology· appears in 29+ cited findings in this library
What it is and how the reviews use it
Annualized relapse rate (ARR) is a key endpoint used in clinical trials for multiple sclerosis (MS). It quantifies the average number of relapses experienced by a patient over a one-year period. In the context of regulatory reviews, ARR serves as a critical measure to assess the efficacy of treatments for MS, often appearing as a primary or secondary endpoint in clinical trials.
The reviews in this library frequently use ARR to demonstrate treatment effects. For instance, the Roche Holding AG — Ocrevus FDA Review reported a relapse rate of 0.29 relapses per year. The Biogen Inc. — Vumerity FDA Review noted an Annualized relapse rate (ARR) with ALKS 8700 of 0.17. Furthermore, the TG THERAPEUTICS, INC — Briumvi FDA Review highlighted an Annualized Relapse Rate (ARR) of 0.09.
Real examples — cited to the source page
| Rebif | Relapse rate | 0.29 | Roche Holding AG — Ocrevus FDA Review, p.198 |
| ALKS 8700 | Annualized relapse rate (ARR) | 0.17 | Biogen Inc. — Vumerity FDA Review, p.56 |
| Kesimpta | Annualized Relapse Rate (ARR) reduction | 50.5% | Novartis AG — Kesimpta FDA Review, p.43 |
| Briumvi | Annualized Relapse Rate (ARR) | 0.09 | TG THERAPEUTICS, INC — Briumvi FDA Review, p.52 |
| Fampyra | MS relapse rate (placebo) | 9 | Merz — Fampyra EMA EPAR variation assessment report, p.28 |
Different drugs were studied in different trials — these values are not head-to-head comparisons.
Explore the full evidence
Every Annualized finding in the library — searchable and answerable in plain language — is in the Neurology research library →
Figures are as stated in the cited source documents. Educational reference only — not medical or investment advice.